Etana Biotechnologies
Seongnam, South Korea· Est.
Affordable Indonesian biopharma focused on recombinant proteins, biosimilars, and future monoclonal antibodies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Affordable Indonesian biopharma focused on recombinant proteins, biosimilars, and future monoclonal antibodies.
OncologyNephrologyAutoimmuneMetabolicHormoneVaccine
Technology Platform
Recombinant protein expression and biosimilar development platform, with emerging capabilities in monoclonal antibody manufacturing.
Opportunities
Rapidly expanding Indonesian biosimilar market and universal health coverage create strong demand for affordable biologics; Etana’s local manufacturing and partnerships position it to capture market share.
Risk Factors
Regulatory approval timelines, competition from multinational biosimilar firms, and the need to maintain cGMP compliance could affect product launch and profitability.
Competitive Landscape
Etana competes with global biosimilar leaders (e.g., Sandoz, Amgen) and regional manufacturers; its differentiation lies in local production, cost advantage, and strategic alliances with innovators like Innovent.